Status:
COMPLETED
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
Lead Sponsor:
Organon and Co
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The primary features of schizophrenia and schizoaffective disorder are characterized by positive (inability to think clearly and distinguish reality from fantasy) and negative symptoms (reduction or a...
Eligibility Criteria
Inclusion
- Subject with schizophrenia or schizoaffective disorder. Subject must sign a written informed consent.
Exclusion
- Have an uncontrolled, unstable, clinically significant medical condition. Have any other psychiatric disorder other than schizophrenia as a primary diagnosis including depression.
Key Trial Info
Start Date :
September 4 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 15 2006
Estimated Enrollment :
1225 Patients enrolled
Trial Details
Trial ID
NCT00212784
Start Date
September 4 2003
End Date
March 15 2006
Last Update
August 15 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.